Johnson & Johnson
NYSE:JNJ
Intrinsic Value
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. [ Read More ]
The intrinsic value of one JNJ stock under the Base Case scenario is 171.49 USD. Compared to the current market price of 156.76 USD, Johnson & Johnson is Undervalued by 9%.
Valuation Backtest
Johnson & Johnson
Run backtest to discover the historical profit from buying and selling JNJ stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Johnson & Johnson's Strong 2023 Sales Growth
2023-Q4 Earnings Call
In Q4 2023, Johnson & Johnson saw worldwide sales of $21.4 billion, up 7.2%, with U.S. growth outpacing international at 11% versus 2.7%. The company's full-year sales reached $85.2 billion, marking a 7.4% increase, and adjusted net earnings rose 6.8% to $25.4 billion. Innovative Medicine's sales grew by 4%, driven by key brands like DARZALEX and ERLEADA, despite losses in exclusivity for ZYTIGA in Europe. MedTech sales surged 13.4% to $7.7 billion, bolstered by the Abiomed acquisition and strong growth in Electrophysiology, though partially offset by Russia sanctions. Margins were pressured by commodity inflation and an unfavorable product mix in MedTech, mitigated by lower costs in Innovative Medicine. R&D investment remained substantial at $4.5 billion.
Balance Sheet Decomposition
Johnson & Johnson
Current Assets | 53.5B |
Cash & Short-Term Investments | 22.9B |
Receivables | 14.9B |
Other Current Assets | 15.7B |
Non-Current Assets | 114.1B |
Long-Term Investments | 4.5B |
PP&E | 20.9B |
Intangibles | 70.7B |
Other Non-Current Assets | 18B |
Current Liabilities | 46.3B |
Accounts Payable | 9.6B |
Accrued Liabilities | 30.2B |
Short-Term Debt | 2B |
Other Current Liabilities | 4.5B |
Non-Current Liabilities | 52.5B |
Long-Term Debt | 25.9B |
Other Non-Current Liabilities | 26.6B |
Earnings Waterfall
Johnson & Johnson
Revenue
|
85.2B
USD
|
Cost of Revenue
|
-26.2B
USD
|
Gross Profit
|
58.9B
USD
|
Operating Expenses
|
-34.7B
USD
|
Operating Income
|
24.3B
USD
|
Other Expenses
|
10.9B
USD
|
Net Income
|
35.2B
USD
|
Free Cash Flow Analysis
Johnson & Johnson
What is Free Cash Flow?
JNJ Profitability Score
Profitability Due Diligence
Johnson & Johnson's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Johnson & Johnson's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
JNJ Solvency Score
Solvency Due Diligence
Johnson & Johnson's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Johnson & Johnson's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for JNJ is 178.55 USD with a low forecast of 158.57 USD and a high forecast of 225.75 USD.
Ownership
JNJ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
JNJ Price
Johnson & Johnson
Average Annual Return | 9.2% |
Standard Deviation of Annual Returns | 2.57% |
Max Drawdown | -27% |
Market Capitalization | 377.3B USD |
Shares Outstanding | 2 409 779 968 |
Percentage of Shares Shorted | 0.62% |
JNJ News
Last Important Events
Johnson & Johnson
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Johnson & Johnson
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Contact
IPO
Employees
Officers
The intrinsic value of one JNJ stock under the Base Case scenario is 171.49 USD.
Compared to the current market price of 156.76 USD, Johnson & Johnson is Undervalued by 9%.